Medical device company DexCom (NASDAQ: DXCM) will be reporting results this Wednesday after market hours. Here’s what to look for.
DexCom beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $1.04 billion, up 12.5% year on year. It was a satisfactory quarter for the company, with a solid beat of analysts’ organic revenue estimates but a miss of analysts’ EPS estimates.
Is DexCom a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting DexCom’s revenue to grow 12.1% year on year to $1.13 billion, slowing from the 15.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.45 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. DexCom has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.3% on average.
Looking at DexCom’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts’ expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%.
Read our full analysis of Boston Scientific’s results here and Intuitive Surgical’s results here.
Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. DexCom is up 2.2% during the same time and is heading into earnings with an average analyst price target of $99.36 (compared to the current share price of $89.20).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
